Sang Gyu Park
Overview
Explore the profile of Sang Gyu Park including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1912
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
An S, Zheng M, Park I, Park S, Noh M, Sung J
Front Immunol
. 2024 Nov;
15:1444777.
PMID: 39483478
It has been demonstrated that CXCL12 inhibits hair growth via CXCR4, and its neutralizing antibody (Ab) increases hair growth in alopecia areata (AA). However, the molecular mechanisms have not been...
2.
Kim S, Um Y, Chung S, Jeong K, Park H, Park K, et al.
World Allergy Organ J
. 2024 Sep;
17(9):100956.
PMID: 39262899
Background: Several biologics have been developed and used to treat severe asthma. However, commercialized biologics have limitations in treating T2-low asthma because their main target is the T2 inflammation marker....
3.
Choi Y, Kim H, Na T, Park K, Park S, Woo S
Invest Ophthalmol Vis Sci
. 2024 Sep;
65(11):11.
PMID: 39240551
Purpose: To investigate the intraocular concentration profiles of stem cell factor (SCF)/c-KIT, galectin-1 (GAL-1), and vascular endothelial growth factor (VEGF)-A with regard to retinal disease and treatment response. Methods: The...
4.
Jeong H, Kim R, Koo H, Choi Y, Kim M, Roh H, et al.
Cardiovasc Res
. 2024 Mar;
120(7):745-755.
PMID: 38507654
Aims: In hypoxia, endothelial cells (ECs) proliferate, migrate, and form new vasculature in a process called angiogenesis. Recent studies have suggested that ECs rely on glycolysis to meet metabolic needs...
5.
Sim Y, Um Y, Park J, Seo M, Park S
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293219
Ovarian cancer is the fifth leading cause of cancer, followed by front line is mostly platinum agents and PARP inhibitors, and very limited option in later lines. Therefore, there is...
6.
Kim K, Kim J, Park S
Mol Cell Biochem
. 2022 Sep;
478(4):861-873.
PMID: 36107283
Given that mast cells are pivotal contributors to allergic diseases, various allergy treatments have been developed to inhibit them. Omalizumab, an anti-immunoglobulin E antibody, is a representative therapy that can...
7.
Kim K, Park J, Kim J, Ko H, Park S
Anticancer Res
. 2022 Jul;
42(7):3453-3461.
PMID: 35790260
Background/aim: Cytotoxic payload conjugation to antibodies efficiently suppresses tumors and contributes to the improvement of cancer survival. In our previous study, c-Kit targeting antibody-drug conjugate (2G4-DM1) with DM1, a microtubule...
8.
Lee J, Kang M, Jang J, Lee J, Yang Y, Choi J, et al.
Sci Rep
. 2022 May;
12(1):8620.
PMID: 35597800
Stem cells are attractive candidates for the regeneration of tissue and organ. Mesenchymal stem cells (MSCs) have been extensively investigated for their potential applications in regenerative medicine and cell therapy....
9.
Kim K, Kim J, Park J, Seo M, Park S
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216379
Lung cancer is the leading cause of cancer-related deaths. Small cell lung cancer (SCLC) accounts for 15-25% of all lung cancers. It exhibits a rapid doubling time and a high...
10.
Seo S, Kim K, Yeo Y, Kim R, Jeong H, Kim J, et al.
Pharmaceutics
. 2021 Aug;
13(8).
PMID: 34452268
Stem cell factor (SCF) and its receptor, cKIT, are novel regulators of pathological neovascularization in the eye, which suggests that inhibition of SCF/cKIT signaling may be a novel pharmacological strategy...